Michael J Donovan

List of Publications by Year
in descending order

82 papers	2,684 citations	279798 23 h-index	197818 49 g-index
86 all docs	86 docs citations	86 times ranked	4734 citing authors

#	Article	IF	Citations
1	Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. Gut, 2023, 72, 129-140.	12.1	90
2	Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies. Prostate Cancer and Prostatic Diseases, 2022, 25, 296-301.	3.9	40
3	Pre-diagnosis urine exosomal RNA (ExoDx EPI score) is associated with post-prostatectomy pathology outcome. World Journal of Urology, 2022, 40, 983-989.	2.2	18
4	Association of mutations in DNA polymerase epsilon with increased CD8+ cell infiltration and prolonged progression-free survival in patients with meningiomas. Neurosurgical Focus, 2022, 52, E7.	2.3	4
5	Global DNA methylation of WTC prostate cancer tissues show signature differences compared to non-exposed cases. Carcinogenesis, 2022, 43, 528-537.	2.8	3
6	Artificial intelligence methods for predictive image-based grading of human cancers. , 2021, , 175-210.		3
7	Peritumoral edema correlates with mutational burden in meningiomas. Neuroradiology, 2021, 63, 73-80.	2.2	13
8	NF2 mutation status and tumor mutational burden correlate with immune cell infiltration in meningiomas. Cancer Immunology, Immunotherapy, 2021, 70, 169-176.	4.2	12
9	USP8 and TP53 Drivers are Associated with CNV in a Corticotroph Adenoma Cohort Enriched for Aggressive Tumors. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 826-842.	3.6	34
10	Payer budget impact of an artificial intelligence inÂvitro diagnostic to modify diabetic kidney disease progression. Journal of Medical Economics, 2021, 24, 972-982.	2.1	6
11	A Drosophila platform identifies a novel, personalized therapy for a patient with adenoid cystic carcinoma. IScience, 2021, 24, 102212.	4.1	23
12	SWI/SNF chromatin remodeling complex alterations in meningioma. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3431-3440.	2.5	15
13	Derivation and validation of a machine learning risk score using biomarker and electronic patient data to predict progression of diabetic kidney disease. Diabetologia, 2021, 64, 1504-1515.	6.3	61
14	Analytical validation of a multi-biomarker algorithmic test for prediction of progressive kidney function decline in patients with early-stage kidney disease. Clinical Proteomics, 2021, 18, 26.	2.1	7
15	Integrated Transcriptome and Network Analysis Reveals Spatiotemporal Dynamics of Calvarial Suturogenesis. Cell Reports, 2020, 32, 107871.	6.4	42
16	A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy. BMC Urology, 2020, 20, 138.	1.4	29
17	Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2â€“10â€‰ng/mL. Prostate Cancer and Prostatic Diseases, 2020, 23, 607-614.	3.9	97
18	Recurrent IDH mutations in high-grade meningioma. Neuro-Oncology, 2020, 22, 1044-1045.	1.2	10

#	Article	IF	Citations
19	STK11 mutation status is associated with decreased survival in meningiomas. Neurological Sciences, 2020, 41, 2585-2589.	1.9	9
20	A first-in-human proof-of-concept trial of intravaginal artesunate to treat cervical intraepithelial neoplasia 2/3 (CIN2/3). Gynecologic Oncology, 2020, 157, 188-194.	1.4	34
21	Initial Validation of a Machine Learning-Derived Prognostic Test (KidneyIntelX) Integrating Biomarkers and Electronic Health Record Data To Predict Longitudinal Kidney Outcomes. Kidney360, 2020, 1, 731-739.	2.1	15
22	289â€…PGV-001: a phase 1 trial of a personalized neoantigen peptide vaccine for the treatment of malignancies in the adjuvant setting. , 2020, , .		0
23	Prostate Cancer in World Trade Center Responders Demonstrates Evidence of an Inflammatory Cascade. Molecular Cancer Research, 2019, 17, 1605-1612.	3.4	21
24	A personalized platform identifies trametinib plus zoledronate for a patient with KRAS-mutant metastatic colorectal cancer. Science Advances, 2019, 5, eaav6528.	10.3	74
25	Molecular Study of Thyroid Cancer in World Trade Center Responders. International Journal of Environmental Research and Public Health, 2019, 16, 1600.	2.6	9
26	Active Cushing Disease Is Characterized by Increased Adipose Tissue Macrophage Presence. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2453-2461.	3.6	13
27	Artificial intelligence in neuropathology: deep learning-based assessment of tauopathy. Laboratory Investigation, 2019, 99, 1019-1029.	3.7	79
28	Multiple immunofluorescence assay identifies upregulation of Active Î²-catenin in prostate cancer. BMC Research Notes, 2019, 12, 68.	1.4	1
29	A phase II open labeled, randomized study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared to Montanide, in melanoma patients in complete clinical remission.. Journal of Clinical Oncology, 2019, 37, 9538-9538.	1.6	3
30	Comparative genomic analysis of driver mutations in matched primary and recurrent meningiomas. Oncotarget, 2019, 10, 3506-3517.	1.8	15
31	Performance of a validated urine exosome gene expression test (EPI) in men within the USPSTF suggested age-group of 55 to 69 years at initial biopsy with a PSA 2-10 ng/mL.. Journal of Clinical Oncology, 2019, 37, 53-53.	1.6	0
32	Spectroscopic analysis with a monolithic micro-structured microsphere fiber probe. , 2019, , .		0
33	A phase I study of the safety and immunogenicity of a multi-peptide personalized genomic vaccine in the adjuvant treatment of solid tumors and hematological malignancies.. Journal of Clinical Oncology, 2019, 37, e14307-e14307.	1.6	2
34	Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. European Urology, 2018, 73, 751-759.	1.9	99
35	The development of a Biobank of cancer tissue samples from World Trade Center responders. Journal of Translational Medicine, 2018, 16, 280.	4.4	9
36	Effective early detection of oral cancer using a simple and inexpensive point of care device in oral rinses. Expert Review of Molecular Diagnostics, 2018, 18, 837-844.	3.1	18

#	Article	IF	Citations
37	A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2â€“10 ng/ml at Initial Biopsy. European Urology, 2018, 74, 731-738.	1.9	186
38	Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial. Clinical Cancer Research, 2018, 24, 4937-4948.	7.0	95
39	Development and validation of a novel automated Gleason grade and molecular profile that define a highly predictive prostate cancer progression algorithm-based test. Prostate Cancer and Prostatic Diseases, 2018, 21, 594-603.	3.9	22
40	Prospective serial sequencing of CTC/cfDNA and NK cell activity in patients undergoing multimodality treatment for triple negative breast cancer.. Journal of Clinical Oncology, 2018, 36, e24108-e24108.	1.6	0
41	Identification of a novel RASD1 somatic mutation in a USP8-mutated corticotroph adenoma. Journal of Physical Education and Sports Management, 2017, 3, a001602.	1.2	8
42	Predicting and replacing the pathological Gleason grade with automated gland ring morphometric features from immunofluorescent prostate cancer images. Journal of Medical Imaging, 2017, 4, 021103.	1.5	5
43	Implementation of a Precision Pathology Program Focused on Oncology-Based Prognostic and Predictive Outcomes. Molecular Diagnosis and Therapy, 2017, 21, 115-123.	3.8	8
44	A metastasis biomarker (MetaSite Breastâ„¢ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer. Npj Breast Cancer, 2017, 3, 42.	5.2	48
45	Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer. Clinical Cancer Research, 2017, 23, 1552-1563.	7.0	65
46	Raman Spectroscopy of Head and Neck Cancer: Separation of Malignant and Healthy Tissue Using Signatures Outside the â€œFingerprintâ€•Region. Biosensors, 2017, 7, 20.	4.7	8
47	Performance of a validated urine exosome gene expression assay to predict high-grade prostate cancer utilizing the International Society of Urological Pathology (ISUP) 2014 grading system.. Journal of Clinical Oncology, 2017, 35, 49-49.	1.6	1
48	Tissue-based analytics provide the next generation of prostate cancer risk models.. Journal of Clinical Oncology, 2017, 35, 236-236.	1.6	0
49	Trials in progress: A phase II study of in situ therapeutic vaccination against refractory solid cancers with intratumoral poly-ICLC.. Journal of Clinical Oncology, 2017, 35, 166-166.	1.6	0
50	Urine Exosomes for Non-Invasive Assessment of Gene Expression and Mutations of Prostate Cancer. PLoS ONE, 2016, 11, e0154507.	2.5	48
51	A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy. JAMA Oncology, 2016, 2, 882.	7.1	458
52	Development and clinical application of an integrative genomic approach to personalized cancer therapy. Genome Medicine, 2016, 8, 62.	8.2	71
53	Intravoxel incoherent motion diffusionâ€weighted imaging of hepatocellular carcinoma: Is there a correlation with flow and perfusion metrics obtained with dynamic contrastâ€enhanced MRI?. Journal of Magnetic Resonance Imaging, 2016, 44, 856-864.	3.4	47
54	In situ, therapeutic vaccination against refractory solid cancers with intratumoral Poly-ICLC: A phase I study.. Journal of Clinical Oncology, 2016, 34, 3086-3086.	1.6	3

#	Article	IF	Citations
55	Transgenic drosophila as a drug-screening platform in colorectal cancer and medullary thyroid cancer.. Journal of Clinical Oncology, 2016, 34, e23164-e23164.	1.6	4
56	Extended analysis of a validated urine-exosome signature to predict high grade prostate cancer on initial biopsy: Performance across multiple sub-groups.. Journal of Clinical Oncology, 2016, 34, 42-42.	1.6	1
57	Advanced tissue-based image analysis techniques integrated with biomarker-morphometric multiplex immunofluorescence to provide prostate cancer risk stratification models post-surgery.. Journal of Clinical Oncology, 2016, 34, 47-47.	1.6	0
58	A non-invasive urine exosome gene expression assay (ExoIntelliScore Prostate) to predict pathologic stage and grade in the prostatectomy specimen.. Journal of Clinical Oncology, 2016, 34, 46-46.	1.6	0
59	Successful development of a first in class tissue-based morphometric approach to re-define prostate cancer Gleason grading and improve risk discrimination at the time of diagnosis.. Journal of Clinical Oncology, 2016, 34, e16610-e16610.	1.6	0
60	Clinical outcomes in genetically targeted cancer treatment.. Journal of Clinical Oncology, 2016, 34, e23127-e23127.	1.6	0
61	Interim performance of a non-DRE urine exosome gene signature to predict Gleason â‰¥7 prostate cancer on initial prostate needle biopsy from patients enrolled in a prospective observational trial.. Journal of Clinical Oncology, 2015, 33, 5064-5064.	1.6	2
62	Window of opportunity trial of HPV E7 antigen-expressing Listeria-based therapeutic vaccination prior to robotic surgery for HPV-positive oropharyngeal cancer.. Journal of Clinical Oncology, 2015, 33, TPS6088-TPS6088.	1.6	1
63	Genomic analysis and personalized cancer therapy for metastatic colorectal cancer.. Journal of Clinical Oncology, 2015, 33, 568-568.	1.6	0
64	Prostate cancer prognosis via integrative and co-localized glandular morphometry and immunofluorescent protein biomarker expression.. Journal of Clinical Oncology, 2015, 33, 262-262.	1.6	1
65	Incorporation of advanced image analysis in novel post-prostatectomy systems pathology models as an approach to replace the clinical Gleason and provide robust risk stratification.. Journal of Clinical Oncology, 2015, 33, e16134-e16134.	1.6	0
66	Genomic analysis in active surveillance. Current Opinion in Urology, 2014, 24, 303-310.	1.8	7
67	Epigenome-wide differences in pathology-free regions of multiple sclerosisâ€“affected brains. Nature Neuroscience, 2014, 17, 121-130.	14.8	239
68	Overcoming tumor heterogeneity in the molecular diagnosis of urological cancers. Expert Review of Molecular Diagnostics, 2014, 14, 1023-1031.	3.1	2
69	Aging-like Phenotype and Defective Lineage Specification in SIRT1-Deleted Hematopoietic Stem and Progenitor Cells. Stem Cell Reports, 2014, 3, 44-59.	4.8	135
70	Gland Ring Morphometry for Prostate Cancer Prognosis in Multispectral Immunofluorescence Images. Lecture Notes in Computer Science, 2014, 17, 585-592.	1.3	5
71	A quantitative image analysis model of prostate biopsies for predicting clinical risk in men enrolled in an active surveillance program.. Journal of Clinical Oncology, 2014, 32, 111-111.	1.6	0
72	A quantitative image analysis model of prostate biopsies for predicting clinical risk in men enrolled in an active surveillance program.. Journal of Clinical Oncology, 2014, 32, e16002-e16002.	1.6	0

#	Article	IF	Citations
73	Association of elevated levels of AR and PAKT in the diagnostic prostate needle biopsy with a greater risk for disease progression: Implications for prognostic models and future treatment decision making.. Journal of Clinical Oncology, 2014, 32, e16007-e16007.	1.6	0
74	2053 URINARY EXOSOMES/MICROVESICLES AS A NON-INVASIVE PLATFORM FOR PROSTATE CANCER ANALYSIS. Journal of Urology, 2013, 189, .	0.4	1
75	Predicting high-risk disease using tissue biomarkers. Current Opinion in Urology, 2013, 23, 245-251.	1.8	18
76	Postoperative systems models more accurately predict risk of significant disease progression than standard risk groups and a 10â€year postoperative nomogram: potential impact on the receipt of adjuvant therapy after surgery. BJU International, 2012, 109, 40-45.	2.5	6
77	1293 PREVIOUSLY DEVELOPED SYSTEMS-BASED BIOPSY MODEL (PROSTATE PX+) IDENTIFIES FAVORABLE-RISK PROSTATE CANCER FOR MEN ENROLLED IN AN ACTIVE SURVEILLANCE PROGRAM. Journal of Urology, 2011, 185, .	0.4	5
78	Systems pathology. Cancer, 2009, 115, 3078-3084.	4.1	21
79	A systems pathology model for predicting overall survival in patients with refractory, advanced non-small-cell lung cancer treated with gefitinib. European Journal of Cancer, 2009, 45, 1518-1526.	2.8	15
80	Personalized Prediction of Tumor Response and Cancer Progression on Prostate Needle Biopsy. Journal of Urology, 2009, 182, 125-132.	0.4	52
81	Systems Pathology Approach for the Prediction of Prostate Cancer Progression After Radical Prostatectomy. Journal of Clinical Oncology, 2008, 26, 3923-3929.	1.6	85
82	Improved prediction of prostate cancer recurrence through systems pathology. Journal of Clinical Investigation, 2007, 117, 1876-1883.	8.2	102